EDAP TMS S.A. (EDAP) has released an update.
EDAP TMS S.A. has reported a 0.8% increase in total revenue for Q1 2024, reaching EUR 14.9 million, with a notable 92% growth in U.S. Focal One HIFU procedures over the previous year. The company is optimistic about the adoption of its Focal One robotic HIFU technology in prostate cancer management, supported by positive study results. Additionally, EDAP is expanding its HIFU applications to women’s health, specifically for treating rectal endometriosis, and anticipates Phase 3 study results in the latter half of 2024.
For further insights into EDAP stock, check out TipRanks’ Stock Analysis page.
